| Annual · values | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -7.41 M USD | -6.07 M USD | -5.77 M USD | -3.64 M USD |
| Depreciation & Amortization | 37599 USD | 27892 USD | 26915 USD | 26566 USD |
| Stock-Based Compensation | 249884 USD | 405025 USD | 248308 USD | 68396 USD |
| Capital Expenditures | 3157 USD | 64455 USD | 18308 USD | 1932 USD |
| Cash Flow from Investing | -30188 USD | -125271 USD | -18308 USD | -1932 USD |
| Cash Flow from Financing | 2.73 M USD | 10.34 M USD | 6.53 M USD | 3.84 M USD |
| Dividends Paid | — | — | — | — |
| Stock Buybacks | — | — | — | — |
| Free Cash Flow | -7.42 M USD | -6.13 M USD | -5.79 M USD | -3.65 M USD |
HeartSciences Inc. is a healthcare company that specializes in the development and commercialization of innovative medical diagnostic solutions. Its primary focus is on cardiac care, aiming to improve the early detection and monitoring of heart disease through advanced technology. HeartSciences is particularly noted for its software-based platform that enhances the capabilities of existing electrocardiogram (ECG) devices by using signal processing and AI-driven algorithms. This enhancement provides medical practitioners with a more detailed analysis of heart conditions, potentially leading to more accurate diagnoses. The company's solutions are designed to be cost-effective and accessible, targeting a range of healthcare facilities, from large hospitals to smaller clinics. HeartSciences is part of the medical technology industry, contributing to the growing field of digital health innovations. By integrating its technology into routine cardiac evaluations, HeartSciences seeks to play a significant role in preventative healthcare and in reducing the burden of cardiovascular diseases globally.